NATIONAL INSTITUTES OF HEALTH SEARCH THIS SITE

Transforming the understanding and treatment of mental illness through research DIVISION OF INTRAMURAL RESEARCH PROGRAMS

OTT - Available Technologies Technologies Available for License The following NIMH technologies are available for license inquiries. Please direct your queries to the NIMH Technology Transfer Office.  For additional information, see our Licensing Information page. To review model PHS license agreements, please stop by our Downloadable Forms and Viewers page. For written inquiries, please contact the NIMH Technology Transfer Office at the following mailing Address: Building 10, Room 4N222 [MSC 1381], National Institutes of Health, Bethesda, MD 20892-1381. Thank you. Novel Isoform of KCNH2 for the Treatment of Schizophrenia Lead inventor: Daniel R. Weinberger The voltage-gated potassium channel, KCNH2, has implications as a genetic risk factor for schizophrenia making it a potential target for therapeutics targeted for schizophrenia and other psychiatric disorders. This particular invention discloses claims for methods of use and development of nucleic acids, polypeptides and antibodies directed towards KCNH2 for determining susceptibility to schizophrenia and the screening for therapeutic agents. IP Protection: US Appl No. 12/593,159 filed 25 Sept 2009 Licensing Information: HHS No. E-245-2006/0 Charlene A. Sydnor sydnorc@mail.nih.gov Related Research Materials: Inducible COMT-Val Mice [E-110-2010] Inducible KCNH2 3.1 Transgenic Mice [E-119-2010] Screen for Cognitive Enhancers and Anti-Epileptics Lead inventor: Dietmar Plenz A novel pattern of locally synchronized activity arising from intrinsic properties of the network of neurons in the frontal cortex that follows power law is called Neuronal Avalanche. A ‘critical state’ for Neuronal Avalanche was determined using distribution of neuronal avalanche size. Based on the determined ‘critical state’ for neuronal avalanche size cognitive functions relating to the prefrontal and frontal cortex can be determined. This invention discloses the use of Neuronal Avalanche Size to screen for drugs that either alter functions of the frontal cortex (working memory, reasoning, decision processing, etc.) or alleviate or promote epileptic activity. IP Protection: US Appl No. 11/990,419 filed 14 Aug 2006 Licensing Information: HHS No. E-294-2005/1 Charlene A. Sydnor sydnorc@mail.nih.gov Collaborative Research Opportunities: Suzanne Winfield winfiels@mail.nih.gov 301 402-4324 Decoding Neuronal Responses for Prosthetic Devices Lead inventor: Barry J. Richmond An algorithm was developed using order statistics to decode neuronal firing rates measured during a motor task. Once measured and decoded a predicted motor outcome can be relayed to a prosthetic device to mimic a given motor activity. This invention discloses methods for decoding neuronal signals that can be translated into instructions for mechanical action of a prosthesis IP Protection: US Patent 7,442,212 issued 28 Oct 2008 Licensing Information: HHS No. E-038-2001/0 Susan Ano anos@mail.nih.gov Collaborative Research Opportunity: Suzanne Winfield winfiels@mail.nih.gov 301-402-4324 Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs NIMH inventor: Maura Furey Available for licensing are new methods of rapidly treating depression. The drugs currently used to treat depression work by increasing the activity at serotonin, norepinephrine and perhaps dopamine receptors in the CNS. However these drugs are effective in only 60-70% of patients, require 3-4 weeks of treatment before clinical improvement and have many side effects. These inventors have shown that in human patients, the administration of anti-muscarinic agents produce a rapid, prolonged alleviation of depressive symptoms. Beginning the day following administration of the anti-muscarinic agent, a majority of patients show significant improvements in mood, anxiety, sleep and other depressive symptoms that last days or weeks. The very slow dissociation of some muscarinic agents from their receptors may account for the prolonged therapeutic effects. IP Protection: US Appl No. 11/137,114 filed 25 May 2005, Licensing Information: HHS No. E-175-2004/0 Jaime M. Greene greenejaime@mail.nih.gov Collaborative Research Opportunity: Suzanne Winfield winfiels@mail.nih.gov 301-402-4324 Other Selected Technologies: High Affinity Ligands for Imaging Human Brain mGlur5 Receptors with PET Inventor: Victor W. Pike HHS No. E-262-2009/0 Potential Therapeutic Drugs for Schizophrenia Inventor:Amanda J. Law HHS No. E-054-2009/0 Prognostic Screen for Effectiveness of Anti-Depressant Medications Inventor: Francis J. McMahon HHS No. E-034-2008/0 Beta-Amyloid PET Imaging Agents Inventor: Lisheng Cai HHS No. E-156-2006/0 Radiotracers for Imaging P-glycoprotein Transporter Function Inventor: Victor Pike HHS No. E-318-2007/0 Collaborative Research Opportunities contact: Suzanne Winfield winfiels@mail.nih.gov 301.402.4324 Licensing Opportunities visit: www.ott.nih.gov OTT Overview OTT Staff Patent Information Material Transfer CRADA Information Licensing Information Available Technology Forms and Agreements NIMH Research OTT Links Office of the Scientific Director Office of the Clinical Director Office of Fellowship Training Office of Technology Transfer Administrative Services Branch Administrative Services Office of the Scientific Director Site Map Participate in Research Contact Us Careers in Research What’s New Principal Investigators Scientists & Clinicians DIRP Labs and Branches DIRP Research Areas Functional MRI Core Magnetic Resonance Core Magnetoencephalography Core Microarray Core Neurophysiology Imaging Facility Scientific and Statistical Computing Core Section on Instrumentation Core Transgenic Core Veterinary Medicine Resources (Staff only)

This page was last updated August 30, 2012.   Site Map Staff Directories Contact NIMH DIRP Employment Opportunities Privacy Notice Policies FOIA Accessibility

The Division of Intramural Research Programs is within the National Institute of Mental Health (NIMH) is a part the National Institutes of Health (NIH), is a component of the U.S. Department of Health and Human Services.